NCT02101710View on ClinicalTrials.gov

Pharmacokinetic Properties of Isosorbide-5-mononitrate Under Fasting and Fed Condition in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Healthy
Interventions
DRUG

Elantan SR 60 mg

"* Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration"

DRUG

Imdur SR 60 mg

"* Trade Name: Elantan~* Active Substance: Isosorbide 5-mononitrate~* Pharmaceutical form: Tablet~* Concentration: 60 mg~* Route of Administration: Oral administration"

Trial Locations (1)

Unknown

1, Jeollabuk-do

All Listed Sponsors
collaborator

Seoul Pharma Laboratories Inc.

INDUSTRY

lead

UCB Korea Co., Ltd.

INDUSTRY

NCT02101710 - Pharmacokinetic Properties of Isosorbide-5-mononitrate Under Fasting and Fed Condition in Healthy Male Subjects | Biotech Hunter | Biotech Hunter